Roche, Glaxo add psychiatric behavior warnings to flu drugs

03/5/2008 | Guardian (London), The

Roche Holding and GlaxoSmithKline PLC -- manufacturers of Tamiflu and Relenza, respectively -- have placed new warnings regarding delirium and abnormal psychiatric behavior on the labels of their influenza medications. The FDA has reviewed reports of neuropsychiatric problems in some patients, primarily in Japan. The drugmakers, however, said on the labels that their drugs' link to these adverse reactions "has not been established."

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC